Primary Immunodeficiency Diseases (PID) Clinical Trial
Official title:
Evaluating the Treatment Experience During Initiation of Subcutaneous Immunoglobulin Replacement (SCIG) Therapy at Home Using Alexa Skill
The main aim of this study is to determine the impact of digital health technology, such as Alexa Skill, used to support the initiation of home-based subcutaneous immunoglobulin (SCIG) treatment, treatment management, and overall participant experience.
This is a non-interventional, observational study to identify relevant concepts of SCIG treatment experience, as well as satisfaction regarding Alexa skill-assisted SCIG initiation, infusion, and disease/therapy management. The study will enroll approximately 36 participants (26 patients/caregivers and 10 healthcare professionals [HCPs]). Participants will be enrolled into following observational Cohorts: - Adult patients with primary immunodeficiency (PID) - Caregivers of patients with a self-reported diagnosis of PID - HCPs who prescribe SCIG for patients with PID Interviews will be conducted by a trained qualitative research interviewer with patients, caregivers, and HCPs, and self-reported data will be collected. This trial will be conducted in the United States. The overall duration of the study will be approximately 4 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03277313 -
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects
|
Phase 3 | |
| Completed |
NCT03716700 -
Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)
|
||
| Active, not recruiting |
NCT05513586 -
A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants
|
Phase 3 | |
| Recruiting |
NCT05986734 -
Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies
|
||
| Completed |
NCT00546871 -
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05755035 -
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
|
Phase 2/Phase 3 | |
| Completed |
NCT02593188 -
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
|
||
| Completed |
NCT03116347 -
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects
|
Phase 4 | |
| Completed |
NCT00157079 -
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
|
Phase 3 | |
| Completed |
NCT01412385 -
Immune Globulin Subcutaenous (Human), 20%
|
Phase 2/Phase 3 | |
| Completed |
NCT00161993 -
Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)
|
Phase 2 | |
| Completed |
NCT01175213 -
Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID
|
Phase 3 | |
| Completed |
NCT01218438 -
Phase 2/3 Study of IGSC, 20% in PIDD
|
Phase 2/Phase 3 | |
| Completed |
NCT05150340 -
A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)
|
Phase 3 | |
| Not yet recruiting |
NCT06076642 -
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
|
Phase 3 | |
| Completed |
NCT00782106 -
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
|
Phase 1/Phase 2 | |
| Completed |
NCT01485796 -
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
|
Phase 2/Phase 3 | |
| Completed |
NCT00814320 -
Gammagard Liquid and rHuPH20 in PID
|
Phase 3 | |
| Completed |
NCT04346108 -
A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)
|
Phase 3 |